ArticlePediatrics2017
Epidemiology of Methicillin-Resistant
Article in Pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 64 citations in OpenAlex.
- S. aureus infections in hospitalized children with hematological, hepatological or kidney diseases over a 16-year period at a tertiary care hospital in Sweden: a retrospective observational study.Italian journal of pediatrics · 2026Observational
- Infantile Vomiting Is Not Always What You Think: The Importance of a Broad Differential Diagnosis.Cureus · 2026Article
- Predictive value of AFR and UCR for the methicillin-resistant Staphylococcus aureus infection in children with bone and joint infection.Scientific reports · 2025Article
- Ertapenem Combined With Anti-The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Use of Daptomycin to Manage Severe MRSA Infections in Humans.Antibiotics (Basel, Switzerland) · 2025Review
- Vancomycin Area Under the Curve to Minimum Inhibitory Concentration Ratio for Treatment Effectiveness in Pediatric and Neonatal Staphylococcal Infections: A Systematic Review.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Association of Antibiotic Route and Outcomes in Children with Methicillin-Resistant Staphylococcus aureus Bacteremic Osteomyelitis.Infectious diseases and therapy · 2025Article
- Risk Factors for Persistent Staphylococcus aureus Bacteremia in Children.The Pediatric infectious disease journal · 2024Observational
- Article
- Genomic Basis of Occurrence of Cryptic Resistance among Oxacillin- and Cefoxitin-SusceptibleMicrobiology spectrum · 2022Article
- Early-onset neonatal sepsis and antibiotic use in Indonesia: a descriptive, cross-sectional study.BMC public health · 2022Article
- Management and Prevention of Staphylococcus aureus Infections in Children.Infectious disease clinics of North America · 2022Review
- Intravenous versus Oral Step-Down for the Treatment ofPharmacy (Basel, Switzerland) · 2022Article
- Reduced Vancomycin Susceptibility, MRSA and Treatment Failure in Pediatric Staphylococcus aureus Bloodstream Infections.The Pediatric infectious disease journal · 2021Article
- Vancomycin Therapeutic Drug Monitoring in Children: New Recommendations, Similar Challenges.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
- Strategies to Prevent Healthcare-Associated Infections: A Narrative Overview.Risk management and healthcare policy · 2020Review
- Evolution of Multi-Resistance to Vancomycin, Daptomycin, and Linezolid in Methicillin-ResistantFrontiers in microbiology · 2020Article
- Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
- Early Bayesian Dose Adjustment of Vancomycin Continuous Infusion in Children: a Randomized Controlled Trial.Antimicrobial agents and chemotherapy · 2019Article
- Differences in gram-positive bacterial colonization and antimicrobial resistance among children in a high income inequality setting.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundMethicillin-resistant
methodsMulticenter, retrospective cohort study of children ≤18 years hospitalized with MRSA bacteremia across 3 tertiary care children's hospitals from 2007 to 2014. Treatment failure was defined as persistent bacteremia >3 days, recurrence of bacteremia within 30 days, or attributable 30-day mortality. Potential risk factors for treatment failure, including the site of infection, vancomycin trough concentration, critical illness, and need for source control, were collected via manual chart review and evaluated using multivariable logistic regression.
resultsOf 232 episodes of MRSA bacteremia, 72 (31%) experienced treatment failure and 23% developed complications, whereas 5 (2%) died within 30 days. Multivariable analysis of 174 children treated with vancomycin with steady-state vancomycin concentrations obtained found that catheter-related infections (odds ratio [OR], 0.36; 95% confidence interval [CI]: 0.13-0.94) and endovascular infections (OR, 4.35; 95% CI: 1.07-17.7) were associated with lower and higher odds of treatment failure, respectively, whereas a first vancomycin serum trough concentration <10 μg/mL was not associated with treatment failure (OR, 1.34; 95% CI, 0.49-3.66). Each additional day of bacteremia was associated with a 50% (95% CI: 26%-79%) increased odds of bacteremia-related complications.
conclusionsHospitalized children with MRSA bacteremia frequently suffered treatment failure and complications, but mortality was low. The odds of bacteremia-related complications increased with each additional day of bacteremia, emphasizing the importance of achieving rapid sterilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.